BMJ  2006;333:705 (30 September), doi:10.1136/bmj.333.7570.705

Letter

Extensively drug resistant tuberculosis

Beware patients lost to follow-up

The first 150 words of the full text of this article appear below.

EDITOR—Lawn and Wilkinson report on the global emergence of extensively drug resistant tuberculosis.¹ An outbreak of extensively drug resistant tuberculosis has been ongoing for a decade in Norway.² In 1994 treatment was started in a patient with pulmonary tuberculosis who was lost to follow-up. One year later, the same patient was admitted to hospital with smear positive, pulmonary, extensively drug resistant tuberculosis.² In the following 10 years, 23 other patients were diagnosed with a strain of Mycobacterium tuberculosis that carried the same IS6110 RFLP and spoligotyping DNA patterns. Of these, 15 had extensively drug resistant tuberculosis (table). Among 3131 patients diagnosed with tuberculosis in Nor-way during these 12 years M tuberculosis was isolated from 2284. Multidrug resistant tuberculosis was identified in 37 of them. The 15 cases of extensively drug resistant tuberculosis in the current outbreak are 0.66% of all culture positive cases and 40% of . . . [Full text of this article]

Norwegian Institute of Public Health, PO Box 4404 Nydalen, 0403 Oslo, Norway ulf.dahle@fhi.no

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

Relevant Article

Extensively drug resistant tuberculosis

Stephen D Lawn and Robert Wilkinson
BMJ 2006 333: 559-560. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

• Villar, R., Vicente, E., Solano, B., Perez-Silanes, S., Aldana, I., Maddry, J. A., Lenaerts, A. J., Franzblau, S. G., Cho, S.-H., Monge, A., Goldman, R. C. (2008). In vitro and in vivo antimycobacterial activities of ketone and amide derivatives of quinoxaline 1,4-di-N-oxide. J Antimicrob Chemother 62: 547-554 [Abstract] [Full text]  
• Vicente, E., Villar, R., Burguete, A., Solano, B., Perez-Silanes, S., Aldana, I., Maddry, J. A., Lenaerts, A. J., Franzblau, S. G., Cho, S.-h., Monge, A., Goldman, R. C. (2008). Efficacy of Quinoxaline-2-Carboxylate 1,4-Di-N-Oxide Derivatives in Experimental Tuberculosis. Antimicrob. Agents Chemother. 52: 3321-3326 [Abstract] [Full text]  
• Migliori, G. B., Loddenkemper, R., Blasi, F., Raviglione, M. C. (2007). 125 years after Robert Koch's discovery of the tubercle bacillus: the new XDR-TB threat. Is "science" enough to tackle the epidemic?. Eur Respir J 29: 423-427 [Full text]  

Online poll

Find out more >>